Pluripotent stem cell replacement approaches to treat type 1 diabetes

Curr Opin Pharmacol. 2018 Dec;43:20-26. doi: 10.1016/j.coph.2018.07.007. Epub 2018 Jul 30.

Abstract

Stem cells represent a potential candidate for β cell replacement in type 1 diabetes. Pluripotent stem cells are able to differentiate in vitro into functional insulin producing cells, that can restore normoglycemia in diabetic mice. Clinical trials with embryonic stem cell-derived pancreatic progenitors are ongoing. Besides, induced pluripotent stem cells offer the chance of personalized cell therapy. So far, transition to the clinic still needs to face critical issues, such as immunogenicity and safety of stem cell derived β cells. To this purpose, new strategies for immunoprotection, including micro and macro-encapsulation, but also gene editing approaches, are being explored.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Differentiation
  • Cell Proliferation
  • Cell Survival
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / pathology
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetes Mellitus, Type 1 / surgery*
  • Embryonic Stem Cells / immunology
  • Embryonic Stem Cells / metabolism
  • Embryonic Stem Cells / transplantation*
  • Graft Survival
  • Humans
  • Induced Pluripotent Stem Cells / immunology
  • Induced Pluripotent Stem Cells / metabolism
  • Induced Pluripotent Stem Cells / transplantation*
  • Insulin-Secreting Cells / immunology
  • Insulin-Secreting Cells / metabolism*
  • Insulin-Secreting Cells / pathology
  • Islets of Langerhans Transplantation / adverse effects
  • Islets of Langerhans Transplantation / methods*
  • Phenotype
  • Regeneration
  • Risk Factors
  • Stem Cell Transplantation / adverse effects
  • Stem Cell Transplantation / methods*
  • Treatment Outcome